Belgian observational survival data (incidence years 2004–2017) and expenditure for innovative oncology drugs in twelve cancer indications-Reference-Cited by-同舟云学术

Belgian observational survival data (incidence years 2004–2017) and expenditure for innovative oncology drugs in twelve cancer indications

Published:2023-03 Issue: Volume:182 Page:23-37
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Neyt Mattias^ORCID,Devos Carl^ORCID,Thiry Nancy,Silversmit Geert^ORCID,De Gendt Cindy^ORCID,Van Damme Nancy^ORCID,Castanares-Zapatero Diego^ORCID,Hulstaert Frank,Verleye Leen^ORCID

Funder

Belgian Health Care Knowledge Centre

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Monitoring Of Reimbursement Significant Expenses MORSE - Rapport 2020 (gegevens 2019): RIZIV - Rijksinstituut voor ziekte- en invaliditeitsverzekering,2020

2. Comparartor report on cancer in Europe 2019 – disease burden, costs and access to medicines;Hofmarcher,2019

3. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13;Davis;BMJ,2017

4. FDA approval and regulation of pharmaceuticals, 1983-2018;Darrow;JAMA,2020

5. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015;Grossmann;Eur J Cancer,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of level of documentation on the accessibility and affordability of new drugs in Norway;Frontiers in Pharmacology;2024-02-14

2. Are We Losing the Final Fight against Cancer?;Cancers;2024-01-19